Le Lézard
Classified in: Health, Business
Subject: RTG

Avid Bioservices Set to Join S&P SmallCap 600


NEW YORK, Oct. 25, 2021 /PRNewswire/ -- Avid Bioservices Inc. (NASD: CDMO) will replace Cadence Bancorporation (NYSE: CADE) in the S&P SmallCap 600 effective prior to the opening of trading on Friday, October 29. S&P MidCap 400 constituent BancorpSouth Bank (NYSE: BXS) is acquiring Cadence Bancorporation in a deal expected to close on or about that date pending final conditions.

Following is a summary of the changes that will take place prior to the open of trading on the effective date:

Effective Date

Index Name      

Action

Company Name

Ticker

GICS Sector

October 29, 2021

S&P SmallCap 600

Addition

Avid Bioservices

CDMO

Health Care


S&P SmallCap 600

Deletion

Cadence Bancorporation

CADE

Financials

For more information about S&P Dow Jones Indices, please visit www.spdji.com

ABOUT S&P DOW JONES INDICES

S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

S&P Dow Jones Indices is a division of S&P Global (NYSE: SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

 

SOURCE S&P Dow Jones Indices


These press releases may also interest you

at 17:44
On Tuesday, May 7, 2024, The Center for Discovery® (TCFD, The Center) honored Edward C. Sweeney, TCFD Board Chair, at the 24th annual Evening of Discovery Gala. The Gala was hosted by Mo Rocca, CBS Sunday Morning Correspondent, Humorist, and Creator...

at 17:30
PT217 is Phanes' first-in-class bispecific antibody targeting DLL3 and CD47; atezolizumab (TECENTRIQ®) is Roche's anti-PD-L1 monoclonal antibodyThe clinical supply agreement will focus on evaluating PT217 in combination with atezolizumab for the...

at 17:30
Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that data from the pre-clinical pharmacokinetics & efficacy study comparing ocular tissue distribution after ocular instillation of tivozanib eye drops will be presented at the upcoming Association...

at 17:19
Long-time Madison podiatrist Colin Graney, DPM, has announced both the closing of his practice and that the Board Certified and Fellowship Trained physicians at Orthopedic & Spine Centers of Wisconsin will provide continuing care for his patients....

at 17:03
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") , a clinical-stage biotechnology company leveraging its proprietary...

at 16:42
Accelerate Diagnostics, Inc. today announced financial preliminary results for the first quarter ended March 31, 2024. "During the...



News published on and distributed by: